Jerry C.Ling

Partner

San Francisco + 1.415.875.5890

Collegati

Condividi

Jerry Ling has earned multiple distinctions for his work representing multinationals in complex disputes and leading internal investigations involving the most significant forms of corporate liability and misconduct. Jerry frequently directs forensic investigations into international data breach and ransomware events and advises management and boards of public companies on strategies for data breach incident response, notice, and disclosure. He also has assisted multiple public companies in obtaining declinations from government authorities after self-disclosing alleged violations involving the Foreign Corrupt Practices Act (FCPA), the False Claims Act (FCA), and inadequate cybersecurity resilience.

Jerry was previously based in China and has more than 20 years of experience counseling multinationals in China on internal investigations, cross-border litigation, and enforcement actions by PRC (the People's Republic of China) authorities, including on PRC anti-bribery, unfair competition, and cybersecurity laws.

Jerry also leads risk assessments and counsels clients with respect to compliance with U.S. and international laws on corruption and internal controls, AI (artificial intelligence) and GenAI (generative AI) technologies, cybersecurity resilience, and data privacy, including the California Consumer Privacy Act (CCPA) and PRC cross-border data transfer, state secrets, and personal information protection laws.

Jerry provides pro bono services to asylum applicants escaping violence in Central America and to domestic abuse victims in the Bay Area.

Esperienze

  • Public company responds to ransomware attackJones Day advised executive management on all aspects of responding to a ransomware attack.
  • Energy company responds to sophisticated ransomware attack by prominent ransomware threat actor groupJones Day directed and coordinated the response to a sophisticated ransomware attack by a well-known criminal threat actor group.
  • Artificial intelligence startup defends data scraping practicesJones Day represented an artificial intelligence and data intelligence company on burgeoning disputes against a leading technology company arising from online data scraping practices.
  • Leading data analytics and data management company develops artificial intelligence policy and strategyJones Day is assisting a leading data analytics and data management company in creating strategies and policies governing use of artificial intelligence tools.
  • Data aggregation company develops virtual private network service that complies with U.S. and foreign privacy lawsJones Day advised a technology company in developing a virtual private network service in compliance with applicable U.S. and foreign data privacy and data security laws.
  • Fortune 100 listed global food company investigates senior China management for misconductJones Day represented a publicly-traded U.S. Fortune 100 company and directed an internal investigation into allegations that senior management of its China operations engaged in self-dealing and bribed Chinese officials.
  • Mobile app developer overhauls its privacy practices to comply with U.S. and EU privacy lawsJones Day assisted a mobile app developer in assessing its privacy practices associated with its consumer apps.
  • Publicly traded U.S. company conducts analysis of notification obligations arising from vendor data breachJones Day advised a publicly traded company on legal notification obligations arising from a data breach and ransomware attack affecting its third party vendor, including an analysis of potential reporting obligations to customers and regulators under GDPR and U.S. laws.
  • Publicly traded U.S. life sciences company investigates unauthorized cyber intrusionJones Day assisted a publicly traded U.S. life sciences company in its response to an unauthorized cyber intrusion and extortion demand.
  • Multinational industrial manufacturer responds to cyberattackJones Day advised a publicly traded multinational industrial manufacturer relating to a sophisticated cyberattack involving global systems.
  • Global technology company conducts compliance analysis of global data security and privacy lawsJones Day advised a technology company regarding enhancing its compliance with statutory, regulatory, and contractual obligations related to data protection, cybersecurity, and privacy applicable to operations in the U.S., Mainland China, India, South America, and Europe.
  • Board committee of U.S. public company conducts internal review of related-party transactionsJones Day represented the special committee of a U.S. public company in connection with its internal investigation of related-party transactions in the U.S. and China involving company founders and senior executives.
  • Major pharmaceutical company arbitrates claims arising out of Chinese investmentsJones Day is representing a major pharmaceutical company in a Hong Kong International Arbitration Centre arbitration arising out of representations and warranties given in respect of the client's investment in a Chinese drug development company whose senior officers and consultants were subsequently prosecuted in the United States for misappropriation of another pharmaceutical company's trade secrets.
  • U.S. listed industrial company investigates senior management in China for conflicts of interest and FCPA violationsJones Day assisted a publicly listed U.S. manufacturer of industrial products with its investigation into allegations that senior management engaged in misconduct in China.
  • Life sciences company resolves FCPA issues with DOJ and SECJones Day represented a publicly traded life sciences company in an internal investigation and resulting self-disclosure to the U.S. Department of Justice ("DOJ") and U.S. Securities and Exchange Commission ("SEC") involving alleged Foreign Corrupt Practices Act ("FCPA") violations arising out of the company's China operations.
  • Salvadoran mother and daughter obtain asylum after fleeing gang persecutionJones Day successfully represented clients S.P. and J.C. in obtaining asylum.
  • Hyster-Yale acquires 75% of Zhejiang Maximal Forklift TruckJones Day advised Hyster-Yale Materials Handling, Inc. in its acquisition of 75% of the outstanding shares of, and a controlling interest in, Zhejiang Maximal Forklift Company Limited from KNSN Pipe and Pile Company Limited.
  • Medical device company assesses FCPA compliance of clinical trial practices in ChinaJones Day assisted a medical device company with a comprehensive assessment of whether previous clinical trial practices and physician arrangements in China potentially violated the FCPA.
  • Public company discloses FCPA issues to DOJ and SECJones Day coordinated the internal investigation and resulting self-disclosure to the U.S. Department of Justice ("DOJ") and the U.S. Securities and Exchange Commission ("SEC") for a public company involved in industrial and manufacturing work regarding Foreign Corrupt Practices Act ("FCPA") issues arising out of the company’s China office.
  • Global private equity firm files claims in HKIAC arbitration against acquisition targetJones Day represented a global private equity firm in a contractual dispute with an acquisition target in Asia.
    •

    October 2024 Alert

    Illinois Becomes Second State to Pass Broad Legislation on the Use of AI in Employment Decisions

    October 2024 Commentary

    SEC's and Private Litigants' Continued Focus on "AI Washing"

    JULY 2024 Alert

    Rhode Island Continues State-Level Adoption of Comprehensive Data Privacy Laws

    June 2024 Alert

    Colorado Enacts AI Consumer Protection Legislation

    MAY 2024 Alert

    California Privacy Protection Agency Publishes Enforcement Advisory on Data Minimization

    April 2024 Alert

    Here We Go Again: U.S. Congress Reintroduces New Comprehensive Federal Privacy Law

    March 2024 Alert

    China Finalizes Provisions on Cross-Border Data Transfer

    March 2024 Alert

    California and FTC Announce Enforcement Actions Involving the Sale of Personal Information

    March 2024 Alert

    California Proposes CCPA Amendments to Further Protect Children's Privacy

    FEBRUARY 2024 Alert

    California Court Greenlights Enforcement of New Privacy Regulations
    Vedi Insight

    • October 22, 2024
      FinAccelerate – Privacy and Cybersecurity Risks and Issues for Fintech and Artificial Intelligence Tools
    • May 21, 2024
      IP, Technology Transactions & Cybersecurity Panel at Digital Assets Week California
    • October 25, 2022
      FinAccelerate – Data Privacy and Cybersecurity Considerations for FinTech Companies
    • February 8, 2022
      2022 Midwest Legal Conference on Privacy & Data Security - Navigating China’s New Data Privacy and Security Laws
    • October 27, 2021
      A False Sense of Security – Your Hidden Risk of Civil and Criminal Liability for Cybersecurity Representations
    • October 14, 2021
      The Impact of China’s New Data Laws on Companies Dealing with U.S. Subpoenas and Document Requests
    • September 21, 2021
      Fifth Annual Latin America Data Protection, Privacy & Cybersecurity Symposium: Beyond Data Breaches - Increasing Risk of Liability for Cybersecurity Misrepresentation
    • September 26, 2019
      Chinese Companies and the FCPA: What Type of Case is Likely to be the First U.S. FCPA Investigation of a Chinese Company?
    • May 1, 2019
      Cybersecurity and Privacy Laws in China and Asia
    • May 15, 2018
      Life Science Seminar: Anti-corruption Regulations
    • May 15, 2018
      Life Science Seminar: PRC Privacy, State Secret and Cybersecurity Laws
    • March 30, 2018
      ACFE Spring Conference 2018: Fraud Investigative Training Workshop - Ask the Experts!
    • October 11, 2017
      What to Do When . . . Your Company Confronts Anti-Corruption Issues in China or India: The Increasing Coordination of U.S. and International Law Enforcement
    • October 2016
      Business Beyond Borders: What You Need to know about Anti Bribery and Corruption in Asia-Pacific
    • January 26, 2016
      CLE Academy Shanghai 2016
    • December 9, 2015
      Global Corruption Risks and Best Practices for the Life Sciences Industry
    • September 17, 2015
      Jones Day Life Science Seminar: Off Label Promotion and FCA Claims; Corruption
    • June 8-9, 2015
      SEC Conference 2015: Update on SEC Enforcement Initiatives for Asia Based Companies
    • June 17, 2014
      SEC Conference 2014: An Accounting and Reporting Update for US Listed Companies Panel speaker for Corporate Fraud & Other Litigation Issues in China
    • May 6, 2014
      The Continuing Expansion of Health Care Enforcement by U.S. and International Authorities: Key Developments and Implications for the Future
    • December 19-20, 2013
      SEC Conference 2013: An Accounting & Reporting Update for US Listed Companies: 1) Update on SEC Enforcement Initiatives for Asia-Based Companies 2) Corporate Fraud in China: Designing & Implementing Effective Anti-Corruption Programs 3) Corporate Fraud in China: Foreign Corrupt Practices Act & Chinese Companies
    • December 12, 2013
      Shanghai In-house Counsel Forum: General Counsel Roundtable - Complying with Data Privacy and State Secrets Laws in Cross-Border Investigations and M&A
    • December 4, 2013
      Daimler Construction Compliance Workshop
    • October 25,2013
      Duke Journal of Comparative and International Law Symposium on Investment in Emerging Markets:The Challenges of Infrastructure Development, Assessing and Protecting against Corruption and other Investment Risks
    • August 28, 2013
      FCPA Roundtable
    • May 3, 2013
      Doing Business in China: Understanding Corruption Risks and Compliance Challenges in China
    • April 30, 2013
      Doing Business in China: Understanding Corruption Risks and Compliance Challenges in China
    • 2012年10月25日
      在华投资研讨会：外商对华投资新的挑战和机遇
    • October 25, 2012
      China Inbound Seminar: New Challenges and Opportunities for Foreign Investments in China
    • October 24, 2012
      Outbound Seminar "Managing Legal Risks in Global Expansion of Chinese Companies"
    • 2012年10月23日
      生命科学法律剧
    • October 23, 2012
      Life Science Legal Drama - "Mr. Big in Wonderland"
    • May 5, 2012
      M&A in China: Conducting FCPA Due Diligence and Creating an Effective and Practical Post-Closing Compliance Policy, 2nd CCH In-House Legal Conference
    • April 12, 2012
      Due Diligence & Business Valuation in M&A Deals 2012: Conducting Corruption Due Diligence for M&A Deals in China

    Prima di procedere all'invio, si prega di notare:

    il contenuto del presente sito web è a scopo esclusivamente informativo e non può essere considerato un parere legale o altro tipo di consulenza professionale. L'invio o la ricezione della presente email non è atta ad instaurare alcun rapporto cliente/avvocato. Le informazioni inviate tramite questa funzione al nostro Studio non saranno coperte da vincolo di riservatezza o confidenzialità fintanto che non ci sia stato conferito e non sia stato da noi accettato un incarico professionale. Inviando il messaggio confermate di aver preso visione e accettato il contenuto di questa informativa.